Clozapine decreases neuropeptide Y-like immunoreactivity and neuropeptide Y mRNA levels in rat nucleus accumbens

European Neuropsychopharmacology

Volumn 9, Issue 4, 1999, Pages 329-335

  Obuchowicz, E ^a,b   Turchan, J ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Clozapine; Neuropeptide Y like immunoreactivity; NPY mRNA; Nucleus accumbens; Rat

Indexed keywords

3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; KETANSERIN; MESSENGER RNA; NEUROPEPTIDE Y; PRAZOSIN; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SULPIRIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; RECEPTOR BINDING;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOPAMINE ANTAGONISTS; IN SITU HYBRIDIZATION; MALE; NEUROPEPTIDE Y; NUCLEUS ACCUMBENS; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; RNA, MESSENGER; SEROTONIN ANTAGONISTS;

EID: 0033153199     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(99)00003-6     Document Type: Article

References (30)

1. Angulo J.A., Cadet J.L., Woolley C.S., Suber F., McEwen B.S. Effect of chronic typical and atypical neuroleptic treatment on proenkephalin mRNA levels in the striatum and nucleus accumbens of the rat. J. Neurochem. 54:1990;1889-1894.
2. Aoki C., Pickel V.M. Neuropeptide Y-containing neurons in the rat striatum: ultrastructure and cellular relations with tyrosine hydroxylase-containing terminals and with astrocytes. Brain Res. 459:1988;205-225.
3. Ashby C.R., Wang R.Y. Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse. 24:1996;349-394.
4. 1-like receptor. J. Pharmacol. Exp. Ther. 284:1998;553-560.
5. Beal M.F., Martin J.B. Effects of neuroleptic drugs on somatostatin-like immunoreactivity. Neurosci. Lett. 47:1984;125-130.
6. De Quidt M.E., Emson P.C. Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system I. Radioimmunoassay and chromatographic characterisation. Neuroscience. 18:1986;527-543.
7. 2 receptor radioligands. Synapse. 22:1996;139-158.
8. Ellenbroek B.A. Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol. Ther. 57:1993;1-78.
9. Frey P. Cholecystokinin octapeptide levels in rat brain are changed after subchronic neuroleptic treatment. Eur. J. Pharmacol. 95:1983;87-92.
10. Gerhardt C.C., van Heerikhuizen H. Functional characteristics of heterologously expressed 5-HT receptors. Eur. J. Pharmacol. 334:1997;1-23.
11. Gygi S.P., Gibb J.W., Hanson G.R. Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions. J. Pharmacol. Exp. Ther. 270:1994;192-197.
12. Heilig M., Widerlöv E. Neurobiology and clinical aspects of neuropeptide Y. Crit. Rev. Neurobiol. 9:1995;115-136.
13. Horn A.S., Cuello A.C., Miller R.J. Dopamine in the mesolimbic system of the rat brain: endogenous levels and the effects of drugs on the uptake mechanism and stimulation of adenylate cyclase activity. J. Neurochem. 22:1974;265-270.
14. Josselyn S.A., Beninger R.J. Neuropeptide Y: intraacumbens injections produce a place preference that is blocked by cis-flupenthixol. Pharmacol. Biochem. Behav. 46:1993;543-552.
15. 2 receptors. Life Sci. 28:1981;1015-1022.
16. Massari V.J., Chan J., Chronwall B.M., O'Donohue T.L., Oertel W.H., Pickel V.M. Neuropeptide Y in the rat nucleus accumbens: ultrastructural localization in aspiny neurons receiving synaptic input from GABAergic terminals. J. Neurosci. Res. 19:1988;171-186.
17. Merchant K.M., Dobie D.J., Filloux F.M., Totzke M., Aravagiri M., Dorsa D.M. Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions. J. Pharmacol. Exp. Ther. 271:1994;460-471.
18. Middlemiss D.N., Tricklebank M.D. Centrally active 5 HT receptor agonists and antagonists. Neurosci. Biobehav. Rev. 16:1992;75-82.
19. Midgley L.P., Bush G.L., Gibb J.W., Hanson G.R. Differential regulation of neuropeptide Y systems in limbic structures of the rat. J. Pharmacol. Exp. Ther. 267:1993;707-713.
20. Midgley L.P., Wagstaff J.D., Singh N.A., Bush L.G., Gibb J.W., Hanson G.R. Dynamic dopaminergic regulation of neuropeptide Y systems in discrete striatal and accumbens regions. Eur. J. Pharmacol. 251:1994;191-199.
21. Obuchowicz E., Turchan J. Effects of acute or long-term treatment with chlorpromazine, haloperidol or sulpiride on neuropeptide Y-like immunoreactivity concentrations in the nucleus accumbens of rat. Eur. Neuropsychopharmacol. 9:(1-2):1999;51-59.
22. Patel S., Freedman S., Chapman K.L., Emms F., Fletcher A.E., Knowles M., Marwood R., McAllister G., Myers J., Patel S., Curtis N., Kulagowski J.J., Leeson P.D., Ridgill M., Graham M., Matheson S., Rathbone D., Watt A.P., Bristow L.J., Rupniak N.M.J., Baskin E., Lynch J.J., Ragan C.I. Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor. J. Pharmacol. Exp. Ther. 283:1997;636-647.
23. Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates, 2nd ed. Academic Press, Sydney.
24. Prinssen E.P.M., Ellenbroek B.A., Cools A.R. Combined antagonism of adrenoceptors and dopamine and 5 HT-receptors underlies the atypical profile of clozapine. Eur. J. Pharmacol. 262:1994;167-170.
25. Sakai K., Maeda K., Okuyama S., Tanaka Ch. Phencyclidine alters regional concentrations of neuropeptide Y and peptide YY in rat brain. Biol. Psychiatry. 40:1996;1246-1254.
26. Salin P., Kerkerian L., Nieoullon A. Expression of neuropeptide Y immunoreactivity in the rat nucleus accumbens is under the influence of the dopaminergic mesencephalic pathway. Exp. Brain Res. 81:1990;363-371.
27. Schotte A., Janssen P.F.M., Megens A.A.H.P., Leysen J.E. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 631:1993;191-202.
28. Shibata K., Haverstick D.M., Bannon M.J. Tachykinin gene expression in rat limbic nuclei: modulation by dopamine antagonists. J. Pharmacol. Exp. Ther. 255:1990;388-392.
29. Waters S.M., Konkoy C.S., Davis T.P. Neuropeptide metabolism on intact, regional brain slices: effect of dopaminergic agents on substance P, cholecystokinin and met-enkephalin degradation. J. Pharmacol. Exp. Ther. 274:1995;783-789.
30. Young W.S. III, Bonner T.I., Brann M.R. Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc. Natl. Acad. Sci. USA. 83:1986;9827-9831.